How does the size of this inducement grant compare to recent hires or similar grants at peer biotech companies?

Schrödinger’s inducement grant of 1,875 RSU shares is modest by biotech‑industry standards. In the last 12 months, comparable senior‑level hires at peer companies such as Moderna (≈4,500–6,000 shares), Vertex (≈5,000–7,000 shares), and CRISPR Therapeutics (≈3,500–5,000 shares) have typically received RSU awards in the 4‑6 k‑share range, reflecting the higher compensation norms for senior scientific or commercial leadership roles. Even at smaller‑cap peers like Beam Therapeutics and Allogene, recent hires have been granted 2,500‑3,500 shares. Consequently, Schrödinger’s 1,875‑share grant suggests the new hires are likely mid‑level (e.g., senior managers or principal scientists) rather than C‑suite executives.

From a trading perspective, the dilution from a 1,875‑share grant is negligible relative to Schrödinger’s ~ 70 million outstanding shares (≈0.003 % impact). The market has historically reacted minimally to similarly sized RSU awards, focusing instead on the strategic value of the hires and the company’s pipeline milestones. Unless the hires are tied to a major upcoming clinical event or partnership, the news is unlikely to move the stock materially. Traders can stay neutral to slightly bullish, monitoring the next 8‑K filing for any additional compensation packages that could signal a larger talent push, and keep an eye on volume spikes around the release—if volume remains muted, the price is likely to continue trending with the broader biotech momentum rather than the grant itself.